PLEASANTON, CA – The National Institutes of Health has awarded an approximately $1.8 million Phase IIB Small Business Innovation Research (SBIR) grant by National Institute of Allergy and Infectious Disease (NIAID) to ambient chemical protection company GenTegra LLC.

The two-year grant will fund the development of filter paper technology for the collection and stabilization of RNA virus in whole blood and plasma at ambient temperatures and for subsequent shipping to and analysis at a centrally located laboratory. “This effort will expand the company’s ability to provide advanced technologies by extending the power of its ambient temperature preservation technology to the field collection of labile microbial pathogens: Zika and other Flavi viruses in particular,” CEO R. Bruce Jamieson said in a statement.

“Our new, paper based technology will also provide formulations that are fully REACH-ECHA compliant,” GenTegra CSO Dr. Michael Hogan added.

Pleasanton, California-based GenTegra LLC is a world leader in developing Active Chemical Protection™ technologies for the ambient dry storage of nucleic acids and other biological molecules and reducing the costs of maintaining biobanks and biorepositories for individual researches, pharmacogenomics companies, and hospitals.

GenTegra LLC has been developing paper-based nucleic acid stabilizing products with its commercialization partner Ahlstrom-Munksjö since 2013 and launched its first commercial product, Ahlstrom-Munksjö GenSaver™ DNA Collection Card, in 2016. The Ahlstrom-Munksjö GenSaver™ card was the result of primary research accomplished under DARPA funded R&D grants and was commercialized using GenTegra’s core technologies for preserving nucleic acids, GenTegra®-DNA and GenTegra®-RNA.

Contact: James Nelson, VP Marketing

[email protected]

1-925-461-3010